Savient Pharmaceuticals, Inc. Obtains Temporary Restraining Order In Patent Infringement Lawsuit Against Sandoz Pharmaceuticals Aand Upsher-Smith Laboratories

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that it was granted late yesterday a Temporary Restraining Order (“TRO”) enjoining all sales of generic oxandrolone tablets by Sandoz Pharmaceuticals, a Novartis Pharmaceuticals company (NYSE: NVS), and Upsher-Smith Laboratories. The TRO was granted in the lawsuit filed yesterday by Savient against Sandoz and Upsher-Smith in the U.S. District Court for the District of New Jersey for infringement of Savient's U.S. Patent Nos. 5,872,147 ("the '147' patent"); 6,090,799 ("the '799 patent"); 6,576,659 ("the '659 patent"); 6,670,351 ("the '351 patent"); and 6,828,313 ("the '313 patent"). These patents relate to various methods of using Savient's product Oxandrin® (oxandrolone tablets, USP) CIII.